CSF Biomarker May Support Lewy Body Diagnosis
A multicohort analysis suggests cerebrospinal fluid DOPA decarboxylase may help distinguish dementia with Lewy bodies and Parkinson’s disease from Alzheimer’s disease and controls
By
Henry Thomas
April 3, 2026
Clinical Scorecard: CSF Biomarker May Support Lewy Body Diagnosis
At a Glance
Category Detail
Condition Lewy body disorders (e.g., Parkinson’s disease, dementia with Lewy bodies) Key Mechanisms Elevated cerebrospinal fluid (CSF) levels of DOPA decarboxylase (DDC) Target Population Patients with Lewy body disorders, Alzheimer’s disease, and cognitively healthy controls Care Setting Clinical and research settings
Key Highlights
CSF DDC levels higher in Lewy body disorders than in controls and Alzheimer’s disease Strong diagnostic performance when incorporating CSF DDC, age, and sex No diagnostic value found for plasma DDC Higher CSF DDC levels associated with parkinsonian symptoms and visual hallucinations Reflects disease-related changes in affected brain regions Guideline-Based Recommendations
Diagnosis
Use CSF DDC levels to support differential diagnosis of Lewy body disorders Management
Further studies needed to evaluate performance across broader patient populations Monitoring & Follow-up
Monitor CSF DDC levels in relation to clinical features of dementia with Lewy bodies Risks
Potential relationships with industry reported by study authors Patient & Prescribing Data
Patients with Lewy body disorders and Alzheimer’s disease
Higher CSF DDC levels observed primarily in patients receiving dopaminergic therapy
Clinical Best Practices
Incorporate CSF DDC measurements in diagnostic evaluations Consider clinical features when interpreting CSF DDC levels Related Resources & Content
